Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR10746(B)] to AMPS
- Suitable for: WB, IP, ICC/IF
- Reacts with: Mouse, Rat, Human
Product nameAnti-AMPS antibody [EPR10746(B)]
See all AMPS primary antibodies
DescriptionRabbit monoclonal [EPR10746(B)] to AMPS
Tested applicationsSuitable for: WB, IP, ICC/IFmore details
Unsuitable for: Flow Cyt or IHC-P
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to Human AMPS.
Database link: P30566
- WB: C6, Raw 264.7, NIH/3T3, HeLa, HepG2 and Jurkat whole cell lysate (ab7899). ICC/IF: HeLa cells. IP: NIH/3T3
Previously labelled as Adenylosuccinate Lyase.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab154872 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 55 kDa.|
|ICC/IF||1/250 - 1/500.|
Tissue specificityUbiquitously expressed. Both isoforms are produced by all tissues. Isoform 2 is 10-fold less abundant than isoform 1.
PathwayPurine metabolism; AMP biosynthesis via de novo pathway; AMP from IMP: step 2/2.
Purine metabolism; IMP biosynthesis via de novo pathway; 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide from 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate: step 2/2.
Involvement in diseaseDefects in ADSL are the cause of adenylosuccinase deficiency (ADSL deficiency) [MIM:103050]. ADSL deficiency is an autosomal recessive disorder characterized by the accumulation in the body fluids of succinylaminoimidazole-carboxamide riboside (SAICA-riboside) and succinyladenosine (S-Ado). Most children display marked psychomotor delay, often accompanied by epilepsy or autistic features, or both, although some patients may be less profoundly retarded. Occasionally, growth retardation and muscular wasting are also present.
Sequence similaritiesBelongs to the lyase 1 family. Adenylosuccinate lyase subfamily.
- Information by UniProt
- Adenylosuccinase antibody
- Adenylosuccinate lyase antibody
- ADSL antibody
All lanes : Anti-AMPS antibody [EPR10746(B)] (ab154872) at 1/1000 dilution
Lane 1 : C6 cell lysate
Lane 2 : Raw 264.7 cell lysate
Lane 3 : NIH/3T3 cell lysate
Lane 4 : HeLa cell lysate
Lane 5 : HepG2 cell lysate
Lane 6 : Jurkat cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 55 kDa
Immunofluorescence analysis of HeLa cells labeling AMPS with ab154872 at 1/250 dilution.
AMPS was immunoprecipitated from 1mg of NIH/3T3 (Mouse embyro fibroblast cells) whole cell extract with ab154872 at 1/40 dilution. Western blot was performed from the immunoprecipitate using ab154872 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1500 dilution.
Lane 1: NIH/3T3 whole cell extract, 10 µg (Input).
Lane 2: ab154872 IP in NIH/3T3 whole cell extract.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab154872 in NIH/3T3 whole cell extract.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 1 seconds
ab154872 has not yet been referenced specifically in any publications.